anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A glycoprotein having the following properties: Molecular weight: 12,000-17,000. Color reactions: Coloring of the protein by the Lowry reaction, coloring of the peptide bond and the amino acid by the ninhydrin reaction after the hydrolysis with hydrochloric acid and coloring of the saccharide by the phenolsulfurinc acid reaction. Properties and solubility: White powder. Soluble in water and aqueous solution of NaCl, etc. and slightly soluble in benzene, etc. Saccharide content: 27-33%. Isoelectric point: 4.2-7.3. Adsorbable in a 0.01M phosphroric acid buffer solution (7.2pH) by specific fractionation procedures. USE:A remedy for tumors. PROCESS:A glycoprotein (CBx) having a very powerful and selective cytotoxic action on the tumorous cells and differentiation inductive action on the recovery of the tumorous cells to the normal cells is obtained by subjecting an extract or cultivation supernatant liquid of a reticuloendothelial cell, lymphoblast, leukemic cell or fibroblastic cell of a warm-blooded animal to a salting out treatment, ion exchange chromatography, gel filtration, affinity chromatography or dialysis, etc. A remedy for tumor is obtd. using said CBx as a main constituent.
Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
OBJECTIVE: To assess whether outcomes of rupture repair differ by aortic repair history and determine the ideal approach for rupture repair in patients with previous aortic repair.
METHODS: This retrospective review included all patients who underwent repair of a ruptured infrarenal abdominal aortic aneurysm from 2003 - 2021 recorded in the Vascular Quality Initiative (VQI) registry. Pre-operative characteristics and post-operative outcomes and long term survival were compared between patients with and without prior aortic repair. To assess the impact of open and endovascular approaches to rupture, a subgroup analysis was then performed among patients who ruptured after a prior infrarenal aortic repair. Univariable and adjusted analyses were performed to account for differences in patient characteristics and operative details.
RESULTS: A total of 6 197 patients underwent rupture repair during the study period, including 337 (5.4%) with prior aortic repairs. Univariable analysis demonstrated an increased 30 day mortality rate in patients with prior repairs vs. without (42 vs. 36%; p = .034), and prior repair was associated with increased post-operative renal failure (35 vs. 21%; p < .001), respiratory complications (32 vs. 24%; p < .001), and wound complications (9 vs. 4%; p < .001). Following adjustment, all outcomes were similar with the exception of bowel ischaemia, which was decreased among patients with prior repair (OR 0.7, 95% CI 0.6 - 0.9). Subgroup analysis demonstrated that patients with a prior aortic repair history who underwent open rupture repair had increased odds for 30 day death (OR 1.3, 95% CI 1.2 - 1.7) and adverse secondary outcomes compared with those managed endovascularly.
CONCLUSION: Prior infrarenal aortic repair was not independently associated with increased morbidity or mortality following rupture repair. Patients with a prior aortic repair history demonstrated statistically significantly higher mortality and morbidity when treated with an open repair compared with an endovascular approach. An endovascular first approach to rupture should be strongly encouraged whenever feasible in patients with prior aortic repair.
ER-phagy, a selective form of autophagic degradation of endoplasmic reticulum (ER) fragments, plays an essential role in governing ER homeostasis. Dysregulation of ER-phagy is associated with the unfolded protein response (UPR), which is a major clue for evoking inflammatory diseases. However, the molecular mechanism underpinning the connection between ER-phagy and disease remains poorly defined. Here, we identified ubiquitin-associated domain-containing protein 2 (UBAC2) as a receptor for ER-phagy, while at the same time being a negative regulator of inflammatory responses. UBAC2 harbors a canonical LC3-interacting region (LIR) in its cytoplasmic domain, which binds to autophagosomal GABARAP. Upon ER-stress or autophagy activation, microtubule affinity-regulating kinase 2 (MARK2) phosphorylates UBAC2 at serine (S) 223, promoting its dimerization. Dimerized UBAC2 interacts more strongly with GABARAP, thus facilitating selective degradation of the ER. Moreover, by affecting ER-phagy, UBAC2 restrains inflammatory responses and acute ulcerative colitis (UC) in mice. Our findings indicate that ER-phagy directed by a MARK2-UBAC2 axis may provide targets for the treatment of inflammatory disease.
Novel compounds of formula (wherein R is H, C 1-3 alkyl, aralkyl, or an aliphatic, aromatic or araliphatic acyl group, R 1 is C 1-5 alkyl, R 2 is C 1-5 alkyl or benzyl, or R 1 and R 2 with the intervening carbon atom form a cycloaliphatic ring, and R 3 is H or methyl) and their physiologically compatible acid addition salts with inorganic or organic acids, are prepared (A) by reducing the corresponding 1- (2 - aminophenyl) - 3,4 - dihydroisoquinolines, any acyl group (R) being retained, reduced or cleaved during this reaction depending upon the reducing agent or (B) by reducing the corresponding 1 - (2 - nitrophenyl) - 3,4 - dihydroisoquinolines either in a single step or in two steps via a 1-(2-nitrophenyl)-1,2,3,4- tetrahydroisoquinoline or (C) by condensing an appropriate 2-phenyl-ethylamine with an appropriate o-aminobenzaldehyde either in a single step or in two steps via a Schiffs base or (D) by condensing an appropriate 2-phenylethylamine with o-nitrobenzaldehyde, reducing the nitro group to amino in the resulting Schiffs base which is then cyclized. Processes A-D yield bases of Formula I which may be salified when required. Product interconversions described are (a) alkylation, aralkylation and acylation of compounds wherein R is H to obtain compounds wherein R is other than H, and (b) reduction of compounds wherein R is acyl to obtain compounds wherein R is alkyl or aralkyl. 1 - 2 - (Aminophenyl) - 3,4 dihydroisoquinolines, with substituents R, R 1 , R 2 and R 3 as in Formula I are prepared by cyclizing oaminobenzonitrile with an appropriate carbinol, followed when required by conversion of R as described at (a) and (b) above. 1 - (2 - Nitrophenyl) - 3,4 - dihydroisoquinolines with substitutents R 1 -R 3 as in Formula I are prepared by cyclizing o-nitrobenzonitrile with an appropriate carbinol. Compounds of Formula I and their compatible addition salts with inorganic and organic acids are stated to possess antiphlogistic and anti-pyretic activity, and may be made up with carriers or excipients into pharmaceutical compositions which may be administed by oral, parenteral or rectal routes.
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
BACKGROUND/OBJECTIVE: Robotic pancreaticoduodenectomy in ampullary cancer has never been studied. This study aimed to clarify the feasibility and justification of robotic pancreaticoduodenectomy in ampullary cancer in terms of surgical risks, and oncologic and survival outcomes.
METHODS: A propensity score-matching comparison of robotic and open pancreaticoduodenectomy based on seven factors commonly used to predict the survival outcomes in ampullary cancer patients.
RESULTS: A total of 147 patients were enrolled, of which 101 and 46 underwent robotic and open pancreaticoduodenectomies, respectively. After propensity score-matching with a 2:1 ratio, 88 and 44 patients in the robotic and open pancreaticoduodenectomy groups were included. The operation time was of no significant difference after matching. The median intraoperative blood loss was much less in those who underwent robotic pancreaticoduodenectomy, both before (median, 120 vs. 320 c.c. P < 0.001) and after (100 vs. 335 mL P < 0.001) score-matching. There were no significant differences in terms of surgical risks, including surgical mortality, surgical morbidity, Clavien-Dindo severity classification, postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage, chyle leak, bile leak, and wound infection, both before or after score-matching. The survival outcomes were also similar between the two groups, regardless of matching.
CONCLUSIONS: Robotic pancreaticoduodenectomy for ampullary cancer is not only technically feasible and safe without increasing surgical risks, but also oncologically justifiable without compromising surgical radicality and survival outcomes.
Standardized allergenic extract is intended for use by physicians who are experienced in the administration of standardized (BAU/mL) allergenic extracts for immunotherapy and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist. Standardized allergenic extracts are not directly interchangeable with other allergenic extracts. The initial dose must be based on skin testing as described in the dosage and administration section of this insert. Patients being switched from other types of extract to standardized allergenic extracts should be started as though they were coming under treatment for the first time. STANDARDIZED CAT HAIR EXTRACT IS NOT INTERCHANGEABLE WITH STANDARDIZED CAT PELT EXTRACTS, STANDARDIZED CAT EXTRACTS LABELED IN AU/mL, OR WITH NON-STANDARDIZED CAT EXTRACTS.

This product should not be injected intravenously. Deep subcutaneous routes have been safe. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and/or death. (See Adverse Reactions)

Serious adverse reactions should be reported to Nelco Laboratories immediately and a report filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, Md. 20852-9787, call 1-800-FDA-1088.

Extreme caution should be taken when using allergenic extracts for patients who are taking beta-blocker medications. In the event of a serious adverse reaction associated with the use of allergenic extracts, patients receiving beta-blockers may not be responsive to epinephrine or inhaled brochodialators. (See Precautions)

Allergenic extracts may be used with caution for patients with unstable or steroid-dependent asthma or with underlying cardiovascular disease. (See Contraindications)
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Cortex Acanthopanacis esophagus cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of glabrous sarcandra herb, Artemisia carvifolia, Cortex Acanthopanacis and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction, concentration and granulation. The granule is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The granule has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The granule fundamentally improves the body functions and prevents and treats cancer cancerization at a low cost in order to recover the health of bodies.
Group (healthy or with psychological or neurological disorder) administered serotonergic psychedelic (psilocybin, DMT, LSD, 5-MeO-DMT, Ayahuasca, etc.) regardless of administration route.
PURPOSE: A high foaming cleansing composition is provided to ensure high stabiliyt at high temperature and excellent cleansing ability. CONSTITUTION: A cleansing composition contains 15.0-30.0 wt% of fatty acid, 5.0-25.0 wt% of potassium hydroxide, and 23 wt% of triethanol amine. The potassium hydroxide and triethanol amine is an alkaline neutralizer. The fatty acid is saturated fatty acid of 12-22 carbon atoms. The composition further contains 5.0-30.0 wt% of polyol. The composition is formed in a cream.
Disclosed herein are methods and compositions for determining and improving the likelihood of response and/or determining and decreasing the likelihood of toxicity to a cellular therapy using metabolomics. Embodiments of the disclosure include methods for measuring certain metabolites in biological samples of an individual for determining whether the individual has a responder or non-responder phenotype to the cellular therapy or to a toxicity of the cellular therapy. Embodiments also include compositions for increasing the response to a cellular therapy or decreasing toxicities associated with a cellular therapy. Embodiments also show that plasma metabolomics correlate with efficacy and toxicities associated with CAR-T therapy towards a cancer. The present disclosure relates to compositions and methods for predicting a subject's response to a CAR T-cell therapy, by analyzing the plasma metabolomics of the subject. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, to improve the efficacy of CAR T-cell therapy.
Arm C will receive a $160 subsidy per month for 3 months to be used on produce.They will see the usual Instacart storefront and will see the discount applied at checkout. They will also receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following the end of the month). They will have Instacart + memberships.
A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of \>20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
Enteral Feeding Tube (EFT) such as Nasogastric Tube (NGT), Duodenal/Jejunal Tube and Gastrostomy Tube are frequently used in Intensive Care Unit (ICU). However, EFT is generally an omitted/neglected source of contamination. EFT can serve as a reservoir of Methicillin Resistant Staphylococcus Aureus (MRSA), which multiplies the risk of mortality by 2-2.5 times, for microorganism transmission. As a consequence of contamination of EFT, microorganisms, that may be manifest with the symptoms such as abdominal pain, distention, nausea, vomiting, diarrhea, may reproduce and progress to bacteremia, septicemia and even to death. In some studies, it is observed that there is a relation between the contamination on the external surface of EFT and contamination on the entry of EFT (hub), and it is also reported that the rate of contamination on the hub of the EFT and the environment of the patient is quite high. ICU nurses are responsible for sustaining safe and secure feeding, medication and fluid replacement of patients. Also, they provide enteral feeding products to patients as they are prescribed. Personnel training, proper processing procedures and developed enteral feeding protocols are shown to decrease the incidence of bacterial contamination on the enteral feeding tube
The Goal of the Proposed Study is to perform an open label, 60 subject, Phase II multi-site clinical trial to investigate the safety and efficacy of intrathecal treatment of aaMSCs in ALS. Patients will be treated with 10-100 million aaMSCs every 3 months for a total of 4 intrathecal injections over 12 months. Reduced dose treatments will be allowed based on specific adverse events. Multiple biomarkers will be tracked throughout the clinical trial and correlated with response to treatment. This study was initially performed at Mayo Clinic in Rochester and subsequently expanded to the two other Mayo Clinic sites in Arizona and Florida. All biopsies and stem cell injections take place at Mayo Clinic Rochester, regardless of where the subject initially enrolls into the study.
Participants will take ASTX029 daily on days 1-21 of each 28-day cycle. ASTX029 should be taken with water on an empty stomach, no food 2 hours before and 2 hours after dose.
The invention discloses a formula of a Hui-nationality Chinese herbal pill for treating esophageal and gastric cancers and a preparation method thereof. The medicine is a green high-tech Chinese herbal medicine for treating esophageal and gastric cancers. The preparation method comprises the following steps: mixing Chinese herbal medicines such as radix sophorae subprostratae, rhizoma curcumae, Araiia chinensis L. root-bark, fiveleaf akebia fruit, etc. according to a certain ratio, adding water and decocting, extracting, and concentrating and pelleting so as to prepare traditional Chinese medicine pills which are used for mainly treating esophageal and gastric cancers as well as treating digestive cancers such as pharyngolaryngeal cancer, colorectal cancer, etc. The invention has the characteristics of less medicinal odour and moderate dosage. The selected medicines are proved through pharmacology experiments of modern medicine to be capable of treating cancers. The medicine can fundamentally improve body functions at low cost and prevent cell cancerization so as to recover body health.
Patients undergo proton or photon VMAT CSI with HA over approximately 45 minutes once daily (QD) for 10 days (Monday-Friday) in the absence of unacceptable toxicity. Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT during screening, as well as additional CT for radiation planning during screening. Additionally, patients undergo magnetic resonance imaging (MRI) throughout the trial. They may also undergo lumbar puncture (LP) or alternative methods for cerebral spinal fluid (CSF) collection.
Many national statements have been made recently about the importance of evidence-based arthritis self-management to improvements in the public's health. The prevalence of arthritis is increasing as the US population ages; the prevalence of arthritis-related disability is higher among Blacks than Whites. Effective arthritis self-management education programs with varying formats have been developed and found effective. Despite this, many Arthritis Foundation chapters and arthritis units of state health departments have found dissemination difficult, and cite the time demands (6 weekly sessions, 2 hours/session) of the classic arthritis self-management education program (ASMP) as a major barrier. Researchers at the University of North Carolina at Chapel Hill and Stanford University will develop and evaluate two "low dose" arthritis self-management programs. The study will be conducted in three phases. Phase One (Development): Researchers will conduct needs assessments with arthritis self-management program disseminators, rheumatologists and other arthritis health professionals, and potential program users to determine preferred content, length, and schedule. Using findings from these assessments, researchers will develop two "low dose" versions of the ASMP. Phase Two (Implementation and Evaluation): Researchers will evaluate the "response" (effectiveness) of both "low dose" interventions in a randomized controlled trial (4 months) and a longitudinal study (one year). We will measure four outcomes: (1) Self-Management Behaviors, (2) Arthritis Self-Efficacy, (3) Health-related Quality of Life (Self-reported Health, Pain, Disability, Fatigue, Activity Limitation, and Health Distress); and (4) Health Care Utilization. A sample of 700 adults with diagnosed arthritis or chronic joint pain, including 200 African Americans, will participate in the study. All data will be gathered via self-administered mailed questionnaires, with telephone follow-up as needed. We will use analysis of co-variance and structural equation modeling to evaluate effectiveness. Researchers will also compare the effectiveness of each new "low dose" program with the effectiveness of existing arthritis self-management education program options. Phase Three (Dissemination): We will consult with arthritis units of state health departments and state chapters of the Arthritis Foundation on program adoption and distribution.
Sleep deprivation (SD) has been reported to have a negative impact on cognitive function. Continuous theta burst stimulation (cTBS) shows certain effects in improving sleep and neurological diseases, and its molecular or cellular role in SD-induced cognition impairment still need further exploration. In this study, C57BL/6 mice were subjected to 48 h of SD and cTBS treatment, and cTBS treatment significantly improved SD-triggered impairment of spatial learning and memory abilities in mice. Additionally, cTBS reduced malondialdehyde levels, increased superoxide dismutase activities, and inhibited the production of inflammatory cytokines, alleviating oxidative stress and inflammation levels in hippocampal tissues of SD model mice. cTBS decreased LC3II/LC3I ratio, Beclin1 protein levels, and LC3B puncta intensity, and elevated p62 protein levels to suppress excessive autophagy in hippocampal tissues of SD-stimulated mice. Then, we proved that inhibiting oxidative stress alleviated inflammation, autophagy, and death of hippocampal neuron cells through an in vitro cellular model for oxidative stress, and cTBS treatment promoted the production of glutathione (GSH), the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and the mRNA expression of GSH synthesis-related genes to enhance antioxidant capacity in hippocampal tissues of SD mice. An Nrf2 inhibitor ML385 or a GSH synthesis inhibitor BSO reversed the alleviating effects of cTBS treatment on oxidative stress-associated damage of hippocampal tissues and cognitive impairment in SD model mice. Altogether, our study demonstrated that cTBS mitigates oxidative stress-associated inflammation and autophagy through activating the Nrf2-mediated GSH synthesis pathway, improving cognitive impairment in SD mice.